Vistagen Therapeutics, Inc. (VTGN)
0.2434
+0.01
(+3.35%)
USD |
NASDAQ |
Sep 10, 15:58
Vistagen Therapeutics Shareholders Equity (Quarterly) : 24.48M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 24.48M |
| March 31, 2026 | 35.52M |
| December 31, 2025 | 50.92M |
| September 30, 2025 | 66.34M |
| June 30, 2025 | 56.76M |
| December 31, 2024 | 81.12M |
| September 30, 2024 | 92.97M |
| June 30, 2024 | 104.80M |
| March 31, 2024 | 114.29M |
| December 31, 2023 | 123.28M |
| September 30, 2023 | 35.65M |
| June 30, 2023 | 6.849M |
| March 31, 2023 | 12.08M |
| December 31, 2022 | 20.67M |
| September 30, 2022 | 29.60M |
| June 30, 2022 | 46.05M |
| March 31, 2022 | 64.72M |
| December 31, 2021 | 79.98M |
| September 30, 2021 | 80.66M |
| June 30, 2021 | 85.62M |
| March 31, 2021 | 91.98M |
| December 31, 2020 | 93.81M |
| September 30, 2020 | 4.223M |
| June 30, 2020 | -5.612M |
| March 31, 2020 | -5.729M |
| Date | Value |
|---|---|
| December 31, 2019 | -6.095M |
| September 30, 2019 | -3.630M |
| June 30, 2019 | 1.626M |
| March 31, 2019 | 7.075M |
| December 31, 2018 | 1.693M |
| September 30, 2018 | 3.989M |
| June 30, 2018 | 3.222M |
| March 31, 2018 | 6.917M |
| December 31, 2017 | 10.26M |
| September 30, 2017 | -1.672M |
| June 30, 2017 | -0.6068M |
| March 31, 2017 | 0.6158M |
| December 31, 2016 | 2.589M |
| September 30, 2016 | 4.087M |
| June 30, 2016 | 6.162M |
| March 31, 2016 | -2.977M |
| December 31, 2015 | -1.598M |
| September 30, 2015 | -1.325M |
| June 30, 2015 | -2.866M |
| March 31, 2015 | -20.54M |
| December 31, 2014 | -17.78M |
| September 30, 2014 | -17.18M |
| June 30, 2014 | -15.19M |
| March 31, 2014 | -12.60M |
| December 31, 2013 | -11.47M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 35.74M |
| Total Liabilities (Quarterly) | 11.26M |
| Debt to Equity Ratio | 0.032 |
| Current Ratio | 3.066 |
| Net Debt Paydown Yield | 1.85% |